Intrahepatic Cholangiocarcinoma (ICC)

Cross-source consensus on Intrahepatic Cholangiocarcinoma (ICC) from 1 sources and 6 claims.

1 sources · 6 claims

Uses

Benefits

Risks & contraindications

Background

Evidence quality

Highlighted claims

ICC accounts for 10–15% of primary liver malignancies and its global incidence is rising. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Radical surgical resection is the only potentially curative treatment for ICC, yet only a subset of patients qualify. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
No standardized neoadjuvant regimen exists for ICC despite evidence supporting pre-surgical treatment. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
Post-resection recurrence rates in ICC reach up to 60% within one to two years. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
NCCN biliary tract cancer guidelines recommend enrolling eligible patients in clinical trials investigating neoadjuvant approaches. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
A cohort study of more than 4,000 patients found a 23% reduction in mortality risk with neoadjuvant therapy followed by surgery versus upfront surgery alone. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial